Meridian Bioscience to Present at the William Blair and Company`s 29th Annual Growth Stock Conference

CINCINNATI--(Business Wire)--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the Company has
been invited to present at the William Blair and Company`s 29th Annual Growth
Stock Conference on Thursday, June 11 at 9:20 a.m. CDT at the Four Seasons
Hotel, Chicago, IL. Jack Kraeutler, Chief Executive Officer, and Bill Motto,
Executive Chairman of the Board, are scheduled to present. A question and answer
session will follow the Company`s presentation. The information provided during
the session may not have been previously disclosed.

Meridian invites investors to listen to management`s remarks on the Company`s
website at www.meridianbioscience.com. The link to the Conference is on our
Investor Relations home page. The archived broadcast will be available for 90
days.

Forward Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from
civil litigation for forward-looking statements accompanied by meaningful
cautionary statements. Except for historical information, this report contains
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
which may be identified by words such as "estimates", "anticipates", "projects",
"plans", "seeks", "may", "will", "expects", "intends", "believes", "should" and
similar expressions or the negative versions thereof and which also may be
identified by their context. Such statements, whether expressed or implied, are
based upon current expectations of the Company and speak only as of the date
made. The Company assumes no obligation to publicly update or revise any
forward-looking statements even if experience or future changes make it clear
that any projected results expressed or implied therein will not be realized.
These statements are subject to various risks, uncertainties and other factors
that could cause actual results to differ materially, including, without
limitation, the following: Meridian's continued growth depends, in part, on its
ability to introduce into the marketplace enhancements of existing products or
new products that incorporate technological advances, meet customer requirements
and respond to products developed by Meridian's competition. While Meridian has
introduced a number of internally developed products, there can be no assurance
that it will be successful in the future in introducing such products on a
timely basis. Ongoing consolidations of reference laboratories and formation of
multi-hospital alliances may cause adverse changes to pricing and distribution.
Recessionary pressures on the economy and the markets in which our customers
operate can change expected results, as well as adverse trends in buying
patterns from customers. Costs and difficulties in complying with laws and
regulations administered by the United States Food and Drug Administration can
result in unanticipated expenses and delays and interruptions to the sale of new
and existing products. Changes in the relative strength or weakness of the U.S.
dollar can also change expected results. One of Meridian's main growth
strategies is the acquisition of companies and product lines. There can be no
assurance that additional acquisitions will be consummated or that, if
consummated, will be successful and the acquired businesses successfully
integrated into Meridian's operations. In addition to the factors described in
this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list
and description of uncertainties, risks and other matters that may affect the
Company which are incorporated by reference into this press release.

Meridian is a fully integrated life science company that manufactures, markets
and distributes a broad range of innovative diagnostic test kits, purified
reagents and related products and offers biopharmaceutical enabling
technologies. Utilizing a variety of methods, these products and diagnostic
tests provide accuracy, simplicity and speed in the early diagnosis and
treatment of common medical conditions, such as gastrointestinal, viral and
respiratory infections. Meridian`s diagnostic products are used outside of the
human body and require little or no special equipment. The Company's products
are designed to enhance patient well-being while reducing the total outcome
costs of healthcare. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology, parasitology and
fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents,
specialty biologicals and related technologies used by biopharmaceutical
companies engaged in research for new drugs and vaccines. The Company markets
its products and technologies to hospitals, reference laboratories, research
centers, veterinary testing centers, physician offices, diagnostics
manufacturers and biotech companies in more than 60 countries around the world.
The Company`s shares are traded through NASDAQ`s Global Select Market, symbol
VIVO. Meridian's website address is www.meridianbioscience.com.

Meridian Bioscience, Inc.
John A. Kraeutler, 513-271-3700
Chief Executive Officer

Copyright Business Wire 2009